Filing Details
- Accession Number:
- 0001179110-13-001926
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2013-02-05 16:47:49
- Reporting Period:
- 2013-02-01
- Filing Date:
- 2013-02-05
- Accepted Time:
- 2013-02-05 16:47:49
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
882095 | Gilead Sciences Inc | GILD | Biological Products, (No Disgnostic Substances) (2836) | 943047598 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1190578 | C John Martin | Gilead Sciences, Inc. 333 Lakeside Drive Foster City CA 94404 | Chairman And Ceo | Yes | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2013-02-01 | 282,242 | $7.63 | 4,287,706 | No | 4 | M | Direct | |
Common Stock | Disposition | 2013-02-01 | 271,242 | $40.40 | 4,016,464 | No | 4 | S | Direct | |
Common Stock | Disposition | 2013-02-01 | 11,000 | $41.00 | 4,005,464 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Non-Qualified Stock option (right to buy) | Disposition | 2013-02-01 | 282,242 | $0.00 | 282,242 | $7.63 |
Common Stock | Non-Qualified Stock option (right to buy) | Acquisiton | 2013-02-01 | 392,750 | $0.00 | 392,750 | $40.56 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
2,822,420 | 2014-01-28 | No | 4 | M | Direct | |
392,750 | 2023-02-01 | No | 4 | A | Direct |
Footnotes
- The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan.
- The options have a five year vesting schedule. 20% vest on the first anniversary of the date of grant. The balance will vest 5% quarterly thereafter until fully vested.
- The options have a four year vesting schedule. 25% of the options will vest on the first anniversary date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.
- Sale prices reported for the transactions reported here range from $39.95 to $40.95. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request.
- Sale prices reported for the transactions reported here range from $40.96 to $41.125. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request.